Table 2. IHC markers (at baseline biopsy) vs progression-free survival (PFS) and overall survival (OS).

Biomarkers (before treatment)	N	Median PFS (95% CI)	P-value	Median OS (95% CI)	P-value
pmTOR			0.005		0.425
<2	15	1.645 (1.421–1.869)		5.526 (3.148–7.905)
⩾2	13	2.763 (1.142–4.384)		6.743 (1.638–11.849)
pS6 kinase			0.150		0.599
<4	16	1.678 (1.484–1.871)		10.822 (NR)
⩾4	12	1.743 (1.360–2.127)		5.526 (3.094–7.958)
pS6 Ser 235/6			0.006		0.224
<3	14	1.612 (1.491–1.732)		5.526 (2.810–8.243)
⩾3	14	2.072 (0.566–3.579)		10.822 (4.332–17.313)
pS6 Ser 240/4			0.001		0.073
<2	13	1.579 (1.347–1.811)		4.638 (2.215–7.061)
⩾2	15	2.763 (1.174–4.352)		10.822 (4.909–16.736)
p4EBP1			0.354		0.117
<2	9	1.743 (1.647–1.840)		10.822 (NR)
⩾2	18	1.743 (1.675–1.811)		5.000 (2.137–7.863)

Abbreviations: NR=not reached; p4EBP1=phosphorylated 4E binding protein 1; pmTOR=phosphorylated mammalian target of rapamycin.